Biller B.M.K.,Massachusetts General Hospital |
Ji H.-J.,LG Life science Ltd |
Ahn H.,LG Life science Ltd |
Savoy C.,Biopartners GmbH |
And 6 more authors.
Pituitary | Year: 2013
The weekly sustained-release recombinant human GH formulation LB03002, showed beneficial effects in GH-deficient (GHD) adults in a previous 26-week double-blind study. Prior studies of long-acting GH preparations in adults have only been conducted for 6 or 8 months, so the effects of longer-term use are unknown; this is important to address, as replacement is given for many years in GHD adults. This open-label, 26-week study extension evaluated longer-term safety and efficacy of LB03002 over 52 weeks in adults with GHD who had previously been randomized to GH, and provides additional safety and efficacy data over 26 weeks in the cohort who had previously been randomized to placebo. Of 147 adults with GHD who completed a preceding study, 136 patients continued in this open-label study to receive LB03002 over an additional 26 weeks. This represented a continuation of long-acting GH for 26 weeks in the cohort who took this medication in the prior study (LB03002 Throughout group), and describes the first use of long-acting GH in the cohort that was randomized to placebo in the prior study (Switched to LB03002 group). The LB03002 dose was adjusted according to serum insulin-like growth factor-I (IGF-I) levels. LB03002 treatment demonstrated mean significant decreases from baseline in fat mass (FM) for both 26 (Switched group, P = 0.001) and 52 weeks (Throughout group, P = 0.002) of 1.11 (1.95) kg and 1.06 (3.16) kg, respectively. Prolonged GH treatment was effective in sustaining the increase in lean body mass (LBM), serum IGF-I and IGFBP-3 levels achieved during the first 26 weeks. Long-term treatment with the sustained-release weekly GH preparation over both 26 and 52 weeks in adults with GHD demonstrated a sustained reduction of FM with a favorable safety profile. This study extends prior knowledge about long-acting GH because it reports the most prolonged treatment of adults with any long-acting GH preparation, thereby confirming the value and safety of such agents for long-term GH replacement. © 2012 Springer Science+Business Media, LLC.
Paun D.,National Institute Of Endocrinology Ciparhon |
Bulgar A.,National Institute Of Endocrinology Ciparhon |
Brehar A.,National Institute Of Endocrinology Ciparhon |
Miulescu R.D.,National Institute Of Endocrinology Ciparhon
Romanian Journal of Diabetes, Nutrition and Metabolic Diseases | Year: 2013
In the last 10 years the incidence of type 2 diabetes (T2DM) in children and adolescents has increased, due to increasing prevalence of obesity in youth. Therefore, the prevalence of diabetes-related complications such as hypertension, hyperlipidemia and microalbuminuria has also increased in pediatric T2DM. The pathogenesis of T2DM in children involves genetic and environmental factors that will determine the increase of insulin resistance and decrease of beta pancreatic insulin secretion. Only metformin and insulin are approved for clinical use in children in the majority of countries. The aim of this paper is to review the benefits of the treatment with metformin in children and adolescents with T2DM. © 2013 ILEX PUBLISHING HOUSE, Bucharest, Roumania.